Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical trial studies how well cesium-131 low-dose rate interstitial brachytherapy works as an organ-preserving radiation technique in the treatment of patients with cervical and endometrial cancer that has come back in the vagina after a period of improvement following pelvic radiation therapy (vaginal recurrence). In cervical and endometrial cancer patients with vaginal recurrence following pelvic radiation therapy, the only curative option involves a major surgical procedure which removes all the contents of the pelvic cavity, such as the uterus, cervix, bladder, rectum, vagina, and vulva. This procedure is complex and comes with many side effects; therefore, a need remains to improve radiation treatment techniques so radiation therapy can be offered as an alternative treatment option for these patients. Cesium-131 low-dose rate interstitial brachytherapy is a form of internal radiation therapy called brachytherapy. It uses grain-of-rice-sized radioactive seeds implanted directly into or near where the tumor has returned. The implanted seeds give off radiation to kill tumor cells for only a short time after they are placed. Most of the radiation is gone within a few weeks. The seeds stay in the body permanently, but they become inactive quickly. Cesium-131 low-dose rate interstitial brachytherapy may be an effective organ-preserving radiation technique for the treatment of cervical and endometrial cancer patients with vaginal recurrence following pelvic radiation therapy
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nawrót raka szyjki maticy lub endometrium w pochwie po poprzedniej radioterapii miednicy
- •Możliwość leczenia nawrotu za pomocą implantu cezem-131
- •Zmiany w pochwie widoczne na badaniach obrazowych (CT, MRI) o wielkości co najmniej 1 cm
- •Poprzednia radioterapia miednicy z powodu raka
- •Dobry stan ogólny (zdolność do wykonywania codziennych czynności)
- •Możliwość zrozumienia i podpisania zgody na uczestnictwo w badaniu
✗ Disqualifies
- •Inny aktywny nowotwór lub nowotwór rozpoznany w ciągu ostatnich 3 lat (z wyjątkami dla raka skóry i raka in situ)
- •Przerzuty raka do węzłów chłonnych widoczne na badaniach w momencie rozpoczęcia badania
- •Przyjęcie leku epoetyna alfa w ciągu ostatniego miesiąca przed badaniem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
University of Kentucky Markey Cancer Center
Lexington, United States
Trial contact
Heather Pavlik
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.